Previous close | 332.50 |
Open | 0.00 |
Bid | 320.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 42,607 |
Market cap | 334.916M |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.24 |
Earnings date | 10 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.50 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
MaxCyte, Inc. ( LON:MXCT ) shareholders that were waiting for something to happen have been dealt a blow with a 28...
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viewing insider transactions for MaxCyte, Inc.'s ( LON:MXCT ) over the last year, we see that insiders were net buyers...
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
MaxCyte ( LON:MXCT ) Full Year 2022 Results Key Financial Results Revenue: US$44.3m (up 31% from FY 2021). Net loss...
Every investor in MaxCyte, Inc. ( LON:MXCT ) should be aware of the most powerful shareholder groups. The group holding...
MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
MaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Insiders who acquired US$166k worth of MaxCyte, Inc.'s ( LON:MXCT ) stock at an average price of US$8.29 in the past 12...
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Not every pick can be a...
MaxCyte, Inc. (MXCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
If you want to know who really controls MaxCyte, Inc. ( LON:MXCT ), then you'll have to look at the makeup of its share...
Good day, and thank you for standing by, and welcome to MaxCyte second quarter 2022 earnings conference call. My name is Sean Menarguez, and I'm the director of investor relations here at MaxCyte. On the call from MaxCyte, we have Doug Doerfler, president and chief executive officer; and Ron Holtz, interim chief financial officer.
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 6.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...